Search

Search Constraints

You searched for: Author/Creator Bereswill, Mareike

Search Results

1. Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry. Issue 9 (20th August 2019)

2. Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry. Issue 9 (8th February 2019)

3. Adalimumab Long‐term Effectiveness in Adalimumab‐Naive Patients With Crohn's Disease: Final Data From PYRAMID Registry: 657. (October 2017)

4. Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial. (8th May 2022)

5. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. (17th July 2017)

6. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. (August 2021)

7. Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. Issue 5 (13th May 2022)

8. Open: Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow‐up in the PYRAMID Registry. (June 2018)

9. PYRAMID Registry: Long‐term Safety and Effectiveness of Adalimumab by Baseline Immunomodulator Use in Patients With Crohn's Disease: 694. (October 2017)

10. PYRAMID Registry: Long‐term Safety of Adalimumab by Age in Patients With Crohn's Disease: 717. (October 2017)